AGIOS PHARMACEUTICALS, INC. (AGIO) research
AGIOS PHARMACEUTICALS, INC.- Sector
- Biotechnology
- Last price
- $34.97
- As of
AGIOS PHARMACEUTICALS, INC. (AGIO): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-07-30.
As of . Source: SEC EDGAR filings for AGIO. Method and limitations.
Share the AGIO intelligence card
See AGIO live in the terminal
Track AGIO's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live AGIO terminal, freeActive signals for AGIO
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +3345% to AGIO (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +249% to AGIO (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 58% of AGIO (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 56% of AGIO (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +113% to AGIO (2026Q2)
FREE, NO ACCOUNT
Every signal on AGIO, as it fires
You are seeing 5 of 24 signals recorded on AGIO since 2026-06-21.
The five above all landed on 2026-09-06. The other 19 were recorded on 3 other days. 21 of the 24 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AGIO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 00847X104 · 2026Q2 | $115.3M | 0.05% | , |
| CITADEL ADVISORS LLCCUSIP 00847X104 · 2026Q2 | $27.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 00847X104 · 2026Q2 | $19.9M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 00847X104 · 2026Q2 | $18.8M | 0.02% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AGIO
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
AGIO mentioned in Kresmion daily briefs
AGIO against its peers
AGIO's operating margin of -873.9% ranks in the 11th percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | AGIO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 54.0M USD | 110M USD | 25 | 13 |
| Operating margin | -873.9% | -87.3% | 11 | 13 |
| Net margin | -764.0% | -74.9% | 10 | 14 |
| Return on equity | -34.6% | -26.6% | 45 | 18 |
Peers (21): MESO, ADMA, VIR, RAPP, GHRS, CMPS, KOD, VCEL, URGN, ZYME, STOK, BHVN, ZBIO, SEPN, XNCR, LKFT, PVLA, NTLA, TYRA, SRPT, BCRX. Left out: COAG (no annual filing), GENB (no annual filing), BRVE (no annual filing), KARD (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (AGIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more AGIO signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to AGIOand get the insider, 13F, options, and confluence read in one view.